HIV/HCV Drug Affordability Project

by Khalil Elouardighi, Director of Advocacy
1. Project Overview
2. Key Result #1: Generic DAA in Malaysia
3. Focus #1: Dollar-Value of Malaysian Generics
4. Key Result #2: Colombian HCV Awareness
5. Focus #2: Lat-Am Reach of Colombian Website
6. Other Key Project Achievements
1. PROJECT OVERVIEW

a. Goals

Improved access to HCV treatment in 7 low- and middle-income countries (LMICs), with emphasis on access for HIV/HCV co-infected patients, by:

- Increasing *government commitment* to fight Hepatitis C
- Strengthening Hepatitis C *policies*
- Increasing Hepatitis C *budget*
1. PROJECT OVERVIEW

b. Countries

- Colombia
- Fundacion
- FARMA
- Brazil
- UAEM
- FOAESP
- BMQ
- GIV
- Morocco
- ALCS
- India
- DNP+
- CoNE Manipur
- Thailand
- TTAG
- Ozone Foundation
- TREAT Asia
- Indonesia
- PKNI
- Spritia Foundation
- Malaysia
- TWN
- MAC
- LTAAG+
**PROJECT OVERVIEW**

**c. Key focus areas**

*HCV awareness* among key populations, health care workers, policymakers, and the general population

*Testing and diagnosis* (including pro-active screening)

*Drug affordability* (including generic use)
KEY RESULT #1

Generic DAA in Malaysia

Our Partners:

MTAAG+
Positive Malaysian Treatment Access & Advocacy Group

TWN
Third World Network

National campaign for generic DAA entry & universal access

- **July 2016**: Campaign launch
- **September 2017**: Malaysian government to issue a **government-use license for sofosbuvir**, the first time any government has issued a government-use license for direct-acting antivirals (DAA).
- **End 2017**: **availability of cheap generic DAA in Malaysia**, thanks to government-use licence.
- **2018**: expected launch of **wide national program** to eliminate Hepatitis C in Malaysia, **based on generic**.
FOCUS #1

**Dollar-Value of Malaysian Generics**

Approx. **500 000 HCV-positive** people in Malaysia

_Last price negotiated for Sofosbuvir before the government-use licence (GUL):_

**$12 000** per cure

_Price that can be obtained after the GUL:_

**$300** per cure

_DAA budget to achieve the 2030 Target (pre-GUL vs. post-GUL):_

**$4.8 billion VS. 120 million**

_Savings from generic: $4.68 billion_
KEY RESULT #2

Colombian HCV Awareness Campaign

Our partner: IFARMA

In collaboration with: LigaSida, AltoCosto

Objectives

Increase *access to treatment*, via:

- Collaborations with health insurances
- Advocacy activities to obtain more affordable drugs

Online Public Awareness Campaign “Regálate Un Minuto”

*Ensure HCV awareness and prevention*

*Increase social demand for diagnostics and treatment*
Regaláte Un Minuto (Give yourself a minute) includes:

- A website that provides news, information, a database and webinars on Hepatitis C: https://www.regalateunminuto.net
- Radio spots that aim at prevention
- A social media campaign: @ReMinuto
- A series of workshops throughout Colombia that target local authorities, health care workers, as well as key and general populations
• **Inclusion of key populations** in national Hepatitis guidelines committees
• **Launch of diagnostics and treatment programs in prisons** (Manipur, India)
• **Speedy registration of daclatasvir** (Indonesia) to facilitate procurement
• **National awareness campaigns** towards key populations
• **Catalytic effect of UNITAID funding**: country partners obtained funds for HCV works from other donors
THANK YOU!

For additional information, please contact

plaid-vhc@coalitionplus.org
www.coalitionplus.org

F facebook.com/coalitionplus T @CoalitionPLUS